Aptar Pharma Forms Pact with BD to Develop Novel Autoinjector
Aptar Pharma has signed a license agreement with BD to jointly develop and bring a new autoinjector to market.
Drug-delivery solutions provider Aptar Pharma, part of AptarGroup, announced that it has signed an exclusive development and license agreement with BD (Becton, Dickinson and Company), a medtech firm, to jointly develop a novel auto-injector using Aptar Pharma’s high-performance, two-step autoinjector technology and prefillable syringes from BD.
Based on feedback from patients and healthcare professionals in a market research conducted by Aptar Pharma, the company will work together with BD to create and optimize a compact device that delivers highly viscous drugs, including some of the new biologics. Aptar Pharma’s autoinjector technology has been designed around the BD Neopak 1-mL long glass prefillable syringe or the BD Hypak for Biotech 1-mL long glass prefillable syringe to optimize robustness and performance of the system.
Under the agreement, Aptar and BD will jointly develop Aptar Pharma’s autoinjector technology platform using BD’s expertise in prefillable syringes and self-injection technologies combined with Aptar Pharma’s innovation and quality-by-design expertise. The two-step autoinjector will be exclusively commercialized by BD as part of their portfolio of autoinjectors.
Source: Aptar Pharma
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
